Ac-LKKTETQ raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-06-03. Anything still debated is marked as such rather than presented as settled.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Calculated for the acetylated heptapeptide |
| Molecular weight | ~889 Da | Monoisotopic mass approximately 889.0 Da |
| Amino acid sequence | Ac-LKKTETQ | N-terminal acetylated seven-residue peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilized solid |
| Solubility class | Water-soluble | Peptides of this size generally dissolve in aqueous media |
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Prephenate is oxidatively decarboxylated with retention of the hydroxyl group to give p-hydroxyphenylpyruvate, which is transaminated using glutamate as the nitrogen source to give tyrosine and α-ketoglutarate.
== Other foreign interventions == Other European Parliament corruption scandals involve foreign interventions. Green Party MEP Viola von Cramon-Taubadel said that Kazakhstan, Azerbaijan and Russia also "systematically purchased influence over an extended period". In 2025 foreign interventions by China were investigated.
=== Relations === The pelvic cavity of the true pelvis has the pelvic floor as its inferior boundary (and the pelvic brim as its superior boundary). The perineum has the pelvic floor as its superior boundary. Posteriorly, the pelvic floor extends into the anal triangle.
== Invertebrates == In insects, synephrine has been found to be a very potent agonist at many invertebrate octopamine receptor preparations, and is even more potent than octopamine at a locust (Schistocerca americana gregaria) nerve-muscle preparation. Synephrine (racemic) is also more potent than octopamine (racemic) at inducing light-emission in the firefly (Photinus species) light organ. Synephrine exhibits similarly high potency in stimulating adenylate cyclase activity and in decreasing clotting time in lobster (Homarus americanus) hematocytes. Racemic synephrine was found to increase cAMP in the abdominal epidermis of the blood-sucking bug, Rhodnius prolixus. Rachinsky reported that synephrine was equipotent with octopamine in stimulating JH (juvenile hormone) release in the corpora allata of honey bee (Apis mellifera), but Woodring and Hoffmann found that synephrine had no effect on the synthesis of JH III, in in vitro preparations from the cricket, Gryllus bimaculatus.
Sources: en.wikipedia.org
==== Arrest and death ==== In 1977, Biko broke his banning order by travelling to Cape Town, hoping to meet Unity Movement leader Neville Alexander and deal with growing dissent in the Western Cape branch of the BCM, which was dominated by Marxists like Johnny Issel. Biko drove to the city with his friend Peter Jones on 17 August, but Alexander refused to meet with Biko, fearing that he was being monitored by the police. Biko and Jones drove back toward King William's Town, but on 18 August they were stopped at a police roadblock near Grahamstown. Biko was arrested for having violated the order restricting him to King William's Town. Unsubstantiated claims have been made that the security services were aware of Biko's trip to Cape Town and that the road block had been erected to catch him. Jones was also arrested at the roadblock; he was subsequently held without trial for 533 days, during which time he was interrogated on numerous occasions. The security services took Biko to the Walmer police station in Port Elizabeth, where he was held naked in a cell with his legs in shackles. On 6 September, he was transferred from Walmer to room 619 of the security police headquarters in the Sanlam Building in central Port Elizabeth, where he was interrogated for 22 hours, handcuffed and in shackles, and chained to a grille. Exactly what happened has never been ascertained, but during the interrogation he was severely beaten by at least one of the ten security police officers. He suffered three brain lesions that resulted in a massive brain haemorrhage on 6 September.
A subsequent large randomized controlled trial (RCT), the "ALternatives To prophylactic Antibiotics for the treatment of Recurrent urinary tract infection in women" (ALTAR) trial, was conducted by the United Kingdom National Health Service (NHS). This study, published in 2022, reported that methenamine (hippurate) was non-inferior to daily low-dose antibiotics for prevention of UTIs. The antibiotics used in the study included nitrofurantoin, trimethoprim, and cephalexin. There was a small and non-significant numerical advantage of antibiotics over methenamine in this trial (~0.5 fewer UTIs per year), but this difference was deemed of limited clinical consequence and was considered to be outweighed by the advantages of methenamine. UTI-free rates over 12 months were 43% with methenamine and 54% with antibiotics. Besides effectiveness in terms of UTI prevention, methenamine demonstrated lower rates of bacterial resistance relative to antibiotic therapy in this trial and in other studies. A 2024 systematic review found that methenamine was non-inferior to antibiotic prophylaxis in the prevention of UTIs in two comparative prospective clinical studies, including the ALTAR trial. Other, older studies found that methenamine was inferior to antibiotics including trimethoprim/sulfamethoxazole, trimethoprim, and nitrofurantoin in preventing or suppressing current UTIs, but these studies were of lower quality. Additional large and high-quality clinical trials of methenamine for UTI prevention are needed as of 2024.
Breast milk contains several anti-infective factors such as bile salt stimulated lipase (protecting against amoebic infections) and lactoferrin (which binds to iron and inhibits the growth of intestinal bacteria). Exclusive breastfeeding until six months of age helps to protect an infant from gastrointestinal infections in both developing and industrialized countries. The risk of death due to diarrhea and other infections increases when babies are either partially breastfed or not breastfed at all. Infants who are exclusively breastfed for the first six months are less likely to die of gastrointestinal infections than infants who switched from exclusive to partial breastfeeding at three to four months. During breastfeeding, approximately 0.25–0.5 grams per day of secretory IgA antibodies pass to the baby via milk. This is one of the important features of colostrum. The main target for these antibodies are probably microorganisms in the baby's intestine. The rest of the body displays some uptake of IgA, but this amount is relatively small. Maternal vaccinations while breastfeeding are safe for almost all vaccines. Additionally, the mother's immunity obtained by vaccination against tetanus, diphtheria, whooping cough, and influenza can protect the baby from these diseases, and breastfeeding can reduce the fever rate after infant immunization. However, smallpox and yellow fever vaccines increase the risk of infants developing vaccinia and encephalitis.
The club relieved Gallas of his captaincy, after he openly questioned his teammates, and Wenger appointed Fàbregas as his successor. Arsenal secured fourth position in the league and reached the semi-finals of the Champions League and FA Cup, but it was a fourth season without silverware. Wenger was subject to criticism from Arsenal fans; he praised the travelling supporters, though referred to a section of the home crowd as treating him "like a murderer". Arsenal finished third in the league in 2009–10 and the team were eliminated in the quarter-finals of the Champions League by Barcelona. Wenger had reached a landmark in October 2009, surpassing George Allison to become Arsenal's longest-serving manager. In August 2010, Wenger signed a further three-year contract to continue his managerial career at Arsenal. His team were on course for a quadruple trophy haul in 2010–11, before defeat to Birmingham City in the 2011 Football League Cup Final, when a mix-up between goalkeeper Wojciech Szczęsny and defender Laurent Koscielny allowed Obafemi Martins to score the winning goal. This was followed by a run of just two wins in eleven Premier League games, to take them from title contenders to a fourth-place finish. Arsenal then made exits in the FA Cup and the Champions League to Manchester United and Barcelona, respectively.
=== Industries and economic zones === Ningxia was a major recipient of China's investment in industrial capacity during the Third Front campaign. Yinchuan Economic and Technological Development Zone was established in 1992. Spanning 32 km2 (12 sq mi), it has an annual economic output Rmb23.7 billion (25.1% up) (US$3.5 billion). Major investors are mainly local enterprises such as Kocel Steel Foundry, FAG Railway Bearing (Ningxia), Ningxia Little Giant Machine Tools, etc. Major industries include machinery and equipment manufacturing, new materials, fine chemicals and the animation industry. Desheng Industrial Park (in Helan County) is a base for about 400 enterprises. The industrial park has industrial chains from Muslim food and commodities to trade and logistics, new materials and bio-pharmaceuticals that has 80 billion yuan in fixed assets. Desheng is looking to be the most promising industrial park in the city. It achieved a total output value of 4.85 billion in 2008, up 40 percent year-on-year. The local government plans to cut taxes and other fees to reduce the burden on local enterprises. The industrial output value reached 2.68 billion yuan in 2008, an increase of 48 percent from a year earlier.
Sources: en.wikipedia.org
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.
No. Thymosin beta-4 is a 43-amino-acid protein, while TB-500 represents only a short N-terminal segment. The two should not be treated as interchangeable in experimental design.
It is often called a thymosin beta-4 fragment, Tβ4 fragment, or Ac-LKKTETQ. The name TB-500 is mainly a commercial or catalog label rather than a formal chemical name.
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.